Singapore Allows Sinovac Vaccine After WHO Emergency Approval
(Bloomberg) -- Singapore will allow the use of Sinovac Biotech Ltd.'s Covid-19 vaccine, after the World Health Organization approved the drug as part of its emergency use listing.
The move means the drug can be administered by private health care providers as part of a program that allows the use of unregistered Covid-19 vaccines, the ministry of health said in a statement Wednesday. The Sinovac vaccine is not part of the national vaccine program.
The World Health Organization authorized the Sinovac vaccine on June 1, paving the way for a wider rollout in countries scrambling for a supply of immunizations. Singapore's decision comes about three months after the country received its first shipment of 200,000 doses of the Sinovac shot on Feb. 23, and amid debate over the efficacy of the vaccine.
The shot, dubbed CoronaVac, has the lowest efficacy rate reported from clinical trials among the frontrunner wave of vaccines: it was found to be just 50.7% effective in preventing symptomatic Covid in a trial in Brazil, barely crossing the minimum threshold required by drug regulators around the world. But real world evidence is emerging that it's far more effective on the ground: In a recent study of around 130,000 Indonesia health workers, it protected 94% against symptomatic infection, 96% against hospitalization, and 98% against death.
Singapore has authorized both the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines, and has one of the best per-capita vaccination rates in Asia, with about 40% of the population having received their first dose. The Southeast Asian nation is allowing school children to be inoculated from this month, as part of its strategy to reopen the economy.
Read More: Singapore Says Concerned About ‘Very Tight' Vaccine Supplies
The health ministry will release more details in the coming days and is also studying the possibility for private health-care institutions to access the stock of 200,000 doses. It is working out the details on pricing, informed consent process and safety of the patients who prefer this vaccine, it said.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.